Literature DB >> 34969655

p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.

Konrad H Stopsack1, Daniela Correia Salles2, J Bailey Vaselkiv3, Sydney T Grob3, Lorelei A Mucci3, Tamara L Lotan4.   

Abstract

Entities:  

Year:  2021        PMID： 34969655      PMCID： PMC9555222          DOI： 10.1016/j.euo.2021.12.003

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN： 2588-9311


× No keyword cloud information.
  4 in total

1.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Authors:  Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

2.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

3.  Aneuploidy drives lethal progression in prostate cancer.

Authors:  Konrad H Stopsack; Charles A Whittaker; Travis A Gerke; Massimo Loda; Philip W Kantoff; Lorelei A Mucci; Angelika Amon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-13       Impact factor: 11.205

4.  Estimation and modeling of the restricted mean time lost in the presence of competing risks.

Authors:  Sarah C Conner; Ludovic Trinquart
Journal:  Stat Med       Date:  2021-02-10       Impact factor: 2.373
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.